Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Genprex Inc
(NQ:
GNPX
)
2.080
-0.130 (-5.88%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
24,145
Open
2.260
Bid (Size)
2.020 (10)
Ask (Size)
2.170 (1)
Prev. Close
2.210
Today's Range
2.010 - 2.260
52wk Range
0.1825 - 7.990
Shares Outstanding
59,409,822
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
12 Health Care Stocks Moving In Friday's Intraday Session
May 31, 2024
Via
Benzinga
GNPX Stock Earnings: Genprex Beats EPS for Q1 2024
May 20, 2024
GNPX stock results show that Genprex beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Performance
YTD
+788.89%
+788.89%
1 Month
-14.75%
-14.75%
3 Month
-38.46%
-38.46%
6 Month
+850.64%
+850.64%
1 Year
+159.97%
+159.97%
More News
Read More
Clinical Trials Commenced for Promising Acclaim-3 Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer: Genprex, Inc. (NASDAQ: GNPX)
May 14, 2024
Via
Get News
New Company Officers Appointed After Promising Preclinical Data on Gene Therapy for Anti-Tumor Mechanisms with Ability to Trigger Cancer Cell Death: Genprex, Inc. (NASDAQ: GNPX)
May 13, 2024
Via
Get News
BioMedNewsBreaks — Genprex Inc. (NASDAQ: GNPX) Announces Participation at Upcoming Investor, Industry Events
May 01, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
12 Health Care Stocks Moving In Friday's Pre-Market Session
April 26, 2024
Via
Benzinga
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Positive Preclinical Data Supporting NPRL2 Gene Therapy
April 02, 2024
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Closes on $6.5M Registered Direct Offering
March 25, 2024
Via
Investor Brand Network
Exposures
Product Safety
TechMediaBreaks – Genprex Inc. (NASDAQ: GNPX) Closes on $6.5M Registered Direct Offering
March 25, 2024
Via
Investor Brand Network
Exposures
Product Safety
12 Health Care Stocks Moving In Tuesday's Intraday Session
March 19, 2024
Via
Benzinga
TinyGemsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $6.5M Registered Direct Offering
March 19, 2024
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $6.5M Registered Direct Offering
March 19, 2024
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Adds Korean Patent for Leading Drug Candidate to Growing International Patent Portfolio
March 13, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
March 06, 2024
Via
Benzinga
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Preclinical Data to be Presented at Upcoming AACR Annual Meeting
March 06, 2024
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces New Research Collaborations, Expansion of Nonclinical Programs into New Therapeutic Indications
February 07, 2024
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces New Research Collaborations, Expansion of Nonclinical Programs into New Therapeutic Indications
February 07, 2024
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation at This Month’s BIO CEO & Investor Conference
February 06, 2024
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Phase2a Expansion of Acclaim-1 Clinical Study Enrolls, Doses First Patient
February 05, 2024
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Phase2a Expansion of Acclaim-1 Clinical Study Enrolls, Doses First Patient
February 05, 2024
Via
Investor Brand Network
Exposures
Product Safety
Dow Turns Lower; Federal Reserve Keeps Rates Unchanged
January 31, 2024
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Why AMD Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
January 31, 2024
Via
Benzinga
Crude Oil Down 2%; Alphabet Shares Fall After Q4 Results
January 31, 2024
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
12 Health Care Stocks Moving In Thursday's Pre-Market Session
January 11, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
January 09, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.